Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2017, Article ID 1796145, 5 pages
https://doi.org/10.1155/2017/1796145
Research Article

Clinical Characteristics in Patients with Triple Negative Breast Cancer

1Department of Surgery, New York University Langone Medical Center, New York, NY, USA
2School of Medicine, New York University Langone Medical Center, New York, NY, USA
3Drexel University, School of Medicine, Philadelphia, PA, USA

Correspondence should be addressed to Freya Schnabel; gro.cmuyn@lebanhcs.ayerf

Received 15 February 2017; Accepted 16 July 2017; Published 17 August 2017

Academic Editor: Debra A. Tonetti

Copyright © 2017 Janet Yeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study,” The Journal of the American Medical Association, vol. 295, no. 21, pp. 2492–2502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. L. Nguyen, A. G. Taghian, M. S. Katz et al., “Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2373–2378, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Sørlie, “Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities,” European Journal of Cancer, vol. 40, no. 18, pp. 2667–2675, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Sørlie, C. M. Perou, and R. Tibshirani, “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar
  5. T. Sørlie, R. Tibshirani, and J. Parker, “Repeated observation of breast tumor subtypes in independent gene expression data sets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, pp. 8418–8423, 2003. View at Publisher · View at Google Scholar
  6. N. U. Lin, A. Vanderplas, M. E. Hughes et al., “Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network,” Cancer, vol. 118, no. 22, pp. 5463–5472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Greenup, A. Buchanan, W. Lorizio et al., “Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort,” Annals of Surgical Oncology, vol. 20, no. 10, pp. 3254–3258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. H. Lips, L. Mulder, A. Oonk et al., “Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers,” British Journal of Cancer, vol. 108, no. 10, pp. 2172–2177, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Palomba, M. Budroni, N. Olmeo et al., “Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia,” Oncology Letters, vol. 7, no. 4, pp. 948–952, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Sharma, J. R. Klemp, B. F. Kimler et al., “Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: Implications for hereditary breast and/or ovarian cancer syndrome testing,” Breast Cancer Research and Treatment, vol. 145, no. 3, pp. 707–714, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. L. A. Newman, J. S. Reis-Filho, M. Morrow, L. A. Carey, and T. A. King, “The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer,” Annals of Surgical Oncology, vol. 22, no. 3, pp. 874–882, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. J. L. Boerner, N. Nechiporchik, K. L. Mueller et al., “Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer,” PLoS ONE, vol. 10, no. 3, Article ID e0119614, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. A.-R. Hartman, R. R. Kaldate, L. M. Sailer et al., “Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer,” Cancer, vol. 118, no. 11, pp. 2787–2795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Gonzalez-Angulo, K. M. Timms, S. Liu et al., “Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer,” Clinical Cancer Research, vol. 17, no. 5, pp. 1082–1089, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Balmaña, O. Díez, I. T. Rubio, and F. Cardoso, “BRCA in breast cancer: ESMO clinical practice guidelines,” Annals of Oncology, vol. 22, no. 6, pp. vi31–vi34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. S. Kwon, A. M. Gutierrez-Barrera, D. Young et al., “Expanding the criteria for BRCA mutation testing in breast cancer survivors,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4214–4220, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. D. Fackenthal and O. I. Olopade, “Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations,” Nature Reviews Cancer, vol. 7, no. 12, pp. 937–948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic/Familial High-Risk Assessment: Breast and Ovarian, (ed 4.2013), National Comprehensive Cancer Network.
  19. K. R. Bauer, M. Brown, R. D. Cress, C. A. Parise, and V. Caggiano, “Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype,” Cancer, vol. 109, no. 9, pp. 1721–1728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Boyle, “Triple-negative breast cancer: epidemiological considerations and recommendations,” Annals of Oncology, vol. 23, no. 6, Article ID mds187, pp. vi7–vi12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. K. C. Amirikia, P. Mills, J. Bush, and L. A. Newman, “Higher population-based incidence rates of triple-negative breast cancer among young African-American women. Implications for breast cancer screening recommendations,” Cancer, vol. 117, no. 12, pp. 2747–2753, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Lund, K. F. Trivers, P. L. Porter et al., “Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA,” Breast Cancer Research and Treatment, vol. 113, no. 2, pp. 357–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. G. J. Morris, S. Naidu, and A. K. Topham, “Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the national cancer institute's surveillance, epidemiology, and end results database,” Cancer, vol. 110, no. 4, pp. 876–884, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. S. Moran, Q. Yang, L. N. Harris, B. Jones, D. P. Tuck, and B. G. Haffty, “Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer,” Cancer, vol. 113, no. 9, pp. 2565–2574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Sharma, J. D. Sharma, A. Sarma et al., “Triple negative breast cancer in people of North East India: Critical insights gained at a regional cancer centre,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 11, pp. 4507–4511, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. G. H. Tan, N. A. Taib, W. Y. Choo et al., “Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country,” Asian Pacific Journal of Cancer Preventionv, vol. 10, pp. 395–398, 2009. View at Google Scholar
  27. C. Villarreal-Garza, J. N. Weitzel, M. Llacuachaqui et al., “The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer,” Breast Cancer Research and Treatment, vol. 150, no. 2, pp. 389–394, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Kim and D. H. Choi, “Distribution of BRCA1 and BRCA2 mutations in asian patients with breast cancer,” Journal of Breast Cancer, vol. 16, no. 4, pp. 357–365, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. R. H. Jack, E. A. Davies, C. Renshaw et al., “Differences in breast cancer hormone receptor status in ethnic groups: A London population,” European Journal of Cancer, vol. 49, no. 3, pp. 696–702, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Lakshmaiah, U. Das, T. Suresh et al., “A study of triple negative breast cancer at a tertiary cancer care center in southern India,” Annals of Medical and Health Sciences Research, vol. 4, no. 6, p. 933, 2014. View at Publisher · View at Google Scholar
  31. V. G. Vogel, “Ongoing data from the breast cancer prevention trials: Opportunity for breast cancer risk reduction,” BMC Medicine, vol. 13, no. 1, article no. 63, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Cuzick, I. Sestak, S. Cawthorn et al., “Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial,” The Lancet Oncology, vol. 16, no. 1, pp. 67–75, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. V. G. Vogel, J. P. Costantino, D. L. Wickerham et al., “Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial,” JAMA, vol. 295, pp. 2727–2741, 2006. View at Google Scholar
  34. L. C. Hartmann, A. C. Degnim, R. J. Santen, W. D. Dupont, and K. Ghosh, “Atypical hyperplasia of the breast-risk assessment and management options,” New England Journal of Medicine, vol. 372, no. 1, pp. 78–89, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. W. D. Dupont and D. L. Page, “Risk factors for breast cancer in women with proliferative breast disease,” The New England Journal of Medicine, vol. 312, no. 3, pp. 146–151, 1985. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Li, J. Liu, Y. Yang et al., “Impact of atypical hyperplasia at margins of breast-conserving surgery on the recurrence of breast cancer,” Journal of Cancer Research and Clinical Oncology, vol. 140, no. 4, pp. 599–605, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. R. G. Roetzheim, J.-H. Lee, W. Fulp et al., “Acceptance and adherence to chemoprevention among women at increased risk of breast cancer,” Breast, vol. 24, no. 1, pp. 51–56, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Pruthi, R. E. Heisey, and T. B. Bevers, “Chemoprevention for breast cancer,” Annals of Surgical Oncology, vol. 22, no. 10, pp. 3230–3235, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Bosch, P. Eroles, R. Zaragoza, J. R. Viña, and A. Lluch, “Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research,” Cancer Treatment Reviews, vol. 36, no. 3, pp. 206–215, 2010. View at Publisher · View at Google Scholar · View at Scopus